Trial · NCT00373880
Effects of Aripiprazole on Cocaine Craving and Self-Administration
NCT00373880, Phase 2, Completed, New York State Psychiatric Institute; results first posted 2017-09-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Aripiprazole on Cocaine Craving and Self-Administration. Trials, record NCT00373880. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00373880
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Aripiprazole on Cocaine Craving and Self-Administration
- NCT number
- NCT00373880
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 26 participants, actual
- Lead sponsor
- New York State Psychiatric Institute
- Conditions
- Cocaine Abuse
- Interventions
- Aripiprazole + Cocaine, Placebo + Cocaine
- First posted
- 2006-09-08
- Last updated
- 2017-09-11
- Results first posted
- 2017-09-11
- Limitations and caveats
The study did not assess whether the medication would be useful in preventing relapse in abstinent cocaine users or whether aripiprazole would be beneficial to cocaine-dependent individuals being treated for a psychiatric comorbidity.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cocaine Self-administration | 5 days | Mean number of cocaine choices as a function of cocaine dose and aripiprazole dose (n=8). Participants sampled the dose of cocaine available for the session and then had five choices to respond for money ($5.00) or cocaine using a modified progressive-ratio schedule. |
| Secondary | Subjective Effects of Cocaine | 5 days | Mean Visual Analog Scale (VAS) ratings (items: "Quality", "Pay for Dose", "Good Drug Effect", and "Cocaine Craving") from 0-100mm as a function of cocaine dose and aripiprazole dose 4 min following a single administration of cocaine (the "sample dose") at the start of the session. For "Quality" item, the perceived quality of the drug is rated. The higher the rating, the better quality the drug was perceived to be. For "Pay for Dose" item, the likelihood that the participant would pay for the drug is indicated. Higher ratings indicate a better likelihood that the person would pay for the dose received. For "Good Drug Effect", the likelihood of feeling a good drug effect is indicated. The higher the number, the more of a good drug effect the person reported. For "Cocaine Craving", the intensity of craving is reported. Higher scores indicate more craving for cocaine. |
| Secondary | Plasma Cocaine | 8 minutes | Mean plasma cocaine levels after a single administration of each cocaine dose as a function of aripiprazole and cocaine dose. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Cocaine Self-administration | 5 days | Eight participants were included in this within-subjects analysis. | Number of Choices | MEAN |
| SECONDARY | Subjective Effects of Cocaine | 5 days | Eight participants were included in this within-subjects analysis. | Scores on a scale of 0-100mm | MEAN |
| SECONDARY | Plasma Cocaine | 8 minutes | Eight participants were included in this within-subjects analysis. | ng/mL | MEAN |
Source ClinicalTrials.gov
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Cocaine Self-administration | Placebo + 0mg Cocaine | 0 | Standard Error 0 | Number of Choices | |
| Cocaine Self-administration | Placebo + 12mg Cocaine | 1.5 | Standard Error 0.5 | Number of Choices | |
| Cocaine Self-administration | Placebo + 25mg Cocaine | 3 | Standard Error 0.5 | Number of Choices | |
| Cocaine Self-administration | Placebo + 50mg Cocaine | 4 | Standard Error 0.5 | Number of Choices | |
| Cocaine Self-administration | Aripiprazole + 0 mg Cocaine | 0.2 | Standard Error 0.1 | Number of Choices | |
| Cocaine Self-administration | Aripiprazole + 12mg Cocaine | 2.8 | Standard Error 0.5 | Number of Choices | |
| Cocaine Self-administration | Aripiprazole + 25mg Cocaine | 3.9 | Standard Error 0.5 | Number of Choices | |
| Cocaine Self-administration | Aripiprazole + 50mg Cocaine | 3.7 | Standard Error 0.5 | Number of Choices | |
| Subjective Effects of Cocaine | Placebo + 0mg Cocaine | Quality | 0 | Standard Error 0 | Scores on a scale of 0-100mm |
| Subjective Effects of Cocaine | Placebo + 12mg Cocaine | Quality | 8.5 | Standard Error 0.5 | Scores on a scale of 0-100mm |
1 to 10 of 48Source ClinicalTrials.gov
See all 48 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Aripiprazole/Placebo, Cocaine | 26 | |
| Overall Study | COMPLETED | Aripiprazole/Placebo, Cocaine | 8 | |
| Overall Study | NOT COMPLETED | Aripiprazole/Placebo, Cocaine | 18 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Aripiprazole vs. Placebo | 0 | 8 |
| Total, all-cause mortality | Placebo | 0 | 8 |
| Total, other adverse events | Aripiprazole vs. Placebo | 0 | 8 |
| Total, other adverse events | Placebo | 0 | 8 |
| Total, serious adverse events | Aripiprazole vs. Placebo | 0 | 8 |
| Total, serious adverse events | Placebo | 0 | 8 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Aripiprazole vs. Placebo vs Placebo: deaths from any cause | Trial comparisons |
| Aripiprazole vs. Placebo vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00373880
GET https://conductscience.org/api/trials/v1/NCT00373880/results?page=2